Deferasirox (Exjade):: A new iron chelator

被引：0
|
作者：
不详
机构：
来源：
MEDICAL LETTER ON DRUGS AND THERAPEUTICS | 2006年 / 48卷 / 1233期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：35 / 36
页数：2
相关论文
共 50 条
  • [31] Iron chelation efficiency of deferasirox (Exjade®, ICL670) in patients with transfusional hemosiderosis
    Porter, J
    Borgna-Pignatti, C
    Baccarani, M
    Saviano, A
    Abish, S
    Malizia, R
    Nick, H
    Opitz, H
    Rabault, B
    Gathmann, I
    Marks, P
    BLOOD, 2005, 106 (11) : 755A - 756A
  • [32] Normal pregnancy in a patient with β-thalassaemia major receiving iron chelation therapy with deferasirox (Exjade®)
    Vini, Dimitra
    Servos, Philippos
    Drosou, Marouso
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2011, 86 (03) : 274 - 275
  • [33] Susceptibility of endocrine, cardiac, and macrophage cell lines to iron-mediated oxidative damage and the cytoprotective effect of the orally active chelator deferasirox (Exjade®, ICL670)
    Glickstein, Hava
    Nick, Hanspeter
    Cabantchik, Zvi I.
    BLOOD, 2007, 110 (11) : 24B - 24B
  • [34] EXPERIENCE WITH THE IRON-CHELATOR DEFERASIROX IN SRI LANKAN PATIENTS WITH THALASSEMIA
    Olivieri, Nancy
    Chandrakumaran, Priya
    Jayawardena, Sanasi
    Sabouhanian, Amir
    Premawardhena, Anuja
    Mettananda, Sachith
    Senadeera, Dulanjalee
    Wadanamby, Sandara
    Walgamage, Malsha
    Walgamage, Thilini
    Seneviratne, Prarthana
    Silva, I.
    Hameed, N.
    Bandara, Dayananda
    Nimal, J. M.
    Chan, Helen
    Shanmugananatham, Saambavy
    Deb, Bhumika
    Yamashita, Robert
    Rees, David
    Allen, Angela
    Weatherall, David
    PEDIATRIC BLOOD & CANCER, 2018, 65
  • [35] Long-term treatment with deferasirox (Exjade®, ICL670), a once-daily oral iron chelator, is effective in patients with transfusion-dependent anemias
    Cappellini, Maria Domenica
    Vichinsky, Elliott
    Galanello, Renzo
    Piga, Antonio
    Williamson, Paul
    Porter, John B.
    BLOOD, 2007, 110 (11) : 816A - 816A
  • [36] Deferasirox: An effective once-daily orally active iron chelator
    Porter, John B.
    DRUGS OF TODAY, 2006, 42 (10) : 623 - 637
  • [37] Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib
    Yamamoto, Naoki
    Yamasaki, Takahiro
    Takami, Taro
    Uchida, Koichi
    Fujisawa, Koichi
    Matsumoto, Toshihiko
    Saeki, Issei
    Terai, Shuji
    Sakaida, Isao
    JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION, 2016, 58 (03) : 202 - 209
  • [38] Long-term efficacy and safety of deferasirox (Exjade®, ICL670), a once-daily oral iron chelator, in patients with sickle cell disease (SCD)
    Vichinsky, Elliott
    Coates, Thomas D.
    Thompson, Alexis A.
    Mueller, Brigitta U.
    Lagrone, Darlene
    Heeney, Matthew M.
    BLOOD, 2007, 110 (11) : 995A - 995A
  • [39] Impact on iron removal of dose reduction for non-progressive serum creatinine increases during treatment with the once-daily, oral iron chelator deferasirox (Exjade®, ICL670).
    Gattermann, N.
    Zoumbos, N.
    Angelucci, E.
    Drelichman, G.
    Siegel, J.
    Glimm, E.
    Alberti, D.
    BLOOD, 2006, 108 (11) : 32B - 32B
  • [40] Deferasirox (Exjade®, ICL670):: A journey into labile iron centers of living cardiomyocytes.
    Cabantchik, ZI
    Link, G
    Glickstein, H
    Ben El, R
    Hershko, C
    Konijn, AM
    Nick, H
    BLOOD, 2005, 106 (11) : 243A - 243A
12345